SUNNYVALE, Calif., Sept. 5, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that it will
showcase its industry-leading motion-synchronization cancer
treatment technologies at the upcoming American Society for
Radiation Oncology (ASTRO) Annual Meeting taking place September 15 - 18, 2019 in Chicago, Illinois. The company will provide
multiple opportunities for attendees to explore its new innovations
in patient-first cancer treatments, including booth presentations
and demonstrations at its Innovation Pavilion (booth #3405) and
presentations at the Accuray Symposium.
Synchrony® Motion Tracking and Correction
Technology¹ for the Radixact®
System to be Unveiled
Accuray has brought
Synchrony®, its exclusive motion synchronization
technology, from the CyberKnife® System to the
Radixact® System. During the meeting, attendees
will have the chance to learn how Synchrony for Radixact
synchronizes the treatment delivery beam with the movement of the
tumor, accurately delivering high doses of radiation directly to
the tumor and minimizing dose to healthy tissue, all while the
patient breathes naturally. Clinicians attending the ASTRO meeting
are invited to the unveiling of Synchrony for Radixact on
Sunday, September 15 at 11:00 am CT at the Accuray booth.
Faster Radiation Treatments with the CyberKnife
System
Meeting attendees can also hear more about the
CyberKnife VOLO™
Optimizer, a next-generation optimizer that enables physicians to
significantly improve operational efficiency by reducing both the
time to create high quality treatment plans and the time it takes
to deliver patient treatments. Clinicians now have an option for
delivering the same highly precise radiosurgery and stereotactic
body radiation therapy treatments they have come to expect with the
CyberKnife System, more quickly and for a wider range of patient
cases.
Accuray Symposium: Clinicians to Share Treatment
Perspectives
At Accuray's Symposium event on
Monday, September 16, 2019 from
12:15pm CT - 1:15pm CT, ASTRO meeting
attendees will hear how 15 years' of dynamic tracking and motion
synchronization leadership has translated into improved patient
outcomes. The symposium panelists will discuss their perspectives
and share best practices on how they have used Accuray's motion
synchronization technologies to transform the way cancer treatments
are delivered.
Symposium panelists will include:
- Symposium Chairman & Introduction: Iris C. Gibbs, M.D., FACR, FASTRO, Stanford University Medical Center, Stanford (CA)
- Clinical Value of Motion Synchronization for Prostate
SBRT: Ronald C. Chen, M.D.
M.P.H., University of North Carolina, Chapel
Hill (NC)
- Clinical Value of Motion Synchronization for Lung SBRT:
Jonathan W. Lischalk, M.D., Medstar
Georgetown University Hospital,
Washington (DC)
- First Site Experience on Real-time Motion Synchronization on
the Radixact System: X. Allen
Li, Ph.D., DABMP, FAAPM, Medical
College of Wisconsin, Milwaukee (WI)
AERO™ Academy Program
Presentations
Live in the Accuray booth, ongoing interactive
discussions with industry experts on topics designed to help
improve clinical practice, including:
- Synchrony Motion Synchronization for the Radixact System
- The CyberKnife VOLO™ Experience
- CyberKnife for Prostate SBRT, Liver and Brain Metastases
- TomoTherapy® for Breast and Advanced Rectal
Cancers
- Medicare Radiation Oncology Alternative Payment Model, What it
Means to Your Practice
The full AERO Academy talk schedule can be found here. Attendees
can also book a personalized demonstration with an Accuray
expert here.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please
visit www.accuray.com or follow us
on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical experiences and results, patient experiences and outcomes,
and the potential benefits of Accuray products. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product offerings
and improvements; the company's ability to develop new products or
improve existing products to meet customers' needs; the company's
limited long-term clinical data supporting the safety and efficacy
of its products, including product improvements, for certain users
and such other risks identified under the heading "Risk Factors" in
the company's annual report on Form 10-K, filed with the Securities
and Exchange Commission (the "SEC") on August 23, 2019 and as updated periodically with
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSL
+1 (781) 684-6610
accuray@mslgroup.com
¹ "Synchrony® Motion Tracking and
Correction Technology" is synonymous with the development name:
"Motion Tracking and Compensation Feature for the
Radixact® Treatment Delivery System"
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-to-set-astro-2019-in-motion-with-patient-first-cancer-treatment-innovations-300912175.html
SOURCE Accuray Incorporated